KTTA Pasithea Therapeutics Corp.
USHealthcareAs of 2026-07-10 16:00
Why KTTA matters now
Pasithea Therapeutics Corp. (KTTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.49 with -1.52% on the session and $3.7M in market capitalization; recent performance reads 1-month -28.84% and YTD -61.24%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.9M, and EPS of $-0.41. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -455.3%.
The latest indexable market news headline is "Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $3.00; recent insider activity includes Krishnan Kartik filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.06
P/S
0.00
EV/EBITDA
2.18
DCF Value
$7.85
FCF Yield
-455.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-57.4%
ROA
-35.0%
ROIC
-40.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.9M | $-0.41 |
| Q4 2025 | $0.00 | $-10.1M | $-0.89 |
| FY 2025 | $0.00 | $-20.4M | $-2.91 |
| Q3 2025 | $0.00 | $-3.0M | $-0.41 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$3.00
Target (Median)
$3.00
Target Range
$3.00 - $3.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.25
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.